March 16, 2019 / 5:33 PM / a month ago

BRIEF-Novartis Late-Breaking Data Further Support Initiation Of Entresto In Hospital

March 16 (Reuters) - Novartis Pharmaceuticals Corp:

* NOVARTIS LATE-BREAKING DATA FURTHER SUPPORT INITIATION OF ENTRESTO IN HOSPITAL AND AS FIRST-CHOICE SYSTOLIC HEART FAILURE THERAPY IN STABILIZED PATIENTS

* NOVARTIS PHARMACEUTICALS - SAFETY, TOLERABILITY AT 12 WEEKS WERE COMPARABLE FOR PATIENTS WHO BEGAN ENTRESTO IN HOSPITAL, WHO SWITCHED FROM ENALAPRIL AT 8 WEEKS

* NOVARTIS PHARMACEUTICALS - DATA FROM 4-WEEK EXTENSION OF PIONEER-HF SUPPORT ENTRESTO AS FIRST-CHOICE TREATMENT UPON SYSTOLIC HEART FAILURE DIAGNOSIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below